Table 3 Response and survival
From: Concurrent whole brain radiotherapy and bortezomib for brain metastasis
Best response in brain# | Median survival | |||||
|---|---|---|---|---|---|---|
CR | PR | mPR | SD | PD | months (range) | |
Study population (n = 24)* | 0 | 4 (17%) | 5 (21%) | 5 (21%) | 8 (33%) | 5 (1.5–17) |
Bortezomib dose group | ||||||
(mg/m2/dose) | ||||||
0.9 (n = 5) | 0 | 1 (20%) | 0 | 1 (20%) | 3 (60%) | 7 (5–11) |
1.1 (n = 4) | 0 | 2 (50%) | 1 (25%) | 1 (25%) | 0 | 5.8 (2.5–7) |
1.3 (n = 4) | 0 | 0 | 3 (75%) | 0 | 1 (25%) | 9.5 (5–12.5) |
1.5 (n = 2) | 0 | 0 | 0 | 0 | 2 (100%) | 11 (5–17) |
1.7 (n = 9)¶ | 0 | 1 (11%) | 1 (11%) | 3 (33%) | 2 (22%) | 4 (1–8) |
Radiation dose | ||||||
30 Gy (3 Gy fractions) | 0 | 4 (100%) | 4 (100%) | 2 (25%) | 7 (87.5%) | 7 (1.5–17) |
37.5 Gy (2.5 Gy fractions)† | 0 | 0 (0%) | 0 | 3 (75%) | 1 (12.5%) | 4 (1.5–8) |